Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FK506 nephrotoxicity.

W F Finn1

  • 1Department of Medicine, University of North Carolina at Chapel Hill 27599-7155, USA. wffinn@med.unc.edu

Renal Failure
|July 23, 1999
PubMed
Summary
This summary is machine-generated.

Tacrolimus (FK506) is an immunosuppressant that can harm kidneys. Its complex with FKBP-12 inhibits calcineurin, leading to reduced renal blood flow and potential irreversible kidney damage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.

Kidney international·2006
Same author

Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.

Clinical nephrology·2006
Same author

Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.

Clinical nephrology·2004
Same author

Urinary biomarkers: roles in risk assessment to environmental and occupational nephrotoxins: monitoring of effects and evaluation of mechanisms of toxicity.

Renal failure·1999
Same author

Urinary biomarkers: recommendations of the Joint European/United States Workshop for future research.

Renal failure·1999
Same author

A safety assessment of fixed combinations of acetaminophen and acetylsalicylic acid, coformulated with caffeine.

Renal failure·1998
Same journal

Impaired fasting glucose is comparable to diabetes mellitus in predicting mortality and cardiovascular events in patients undergoing peritoneal dialysis: the role of β-cell function and insulin resistance.

Renal failure·2026
Same journal

Pentoxifylline and cardiorenal outcomes in advanced CKD with untreated dyslipidemia: a longitudinal cohort study.

Renal failure·2026
Same journal

Risk factors and temporal trends of early urological complications after kidney transplantation: a 15-year single-center cohort study.

Renal failure·2026
Same journal

SGLT2 inhibitors and chronic kidney disease: a narrative review of nephroprotective mechanisms from hemodynamics to metabolism.

Renal failure·2026
Same journal

Hypoxia-inducible factor-1α promotes epithelial-to-mesenchymal transition through upregulating cathepsin S expression in diabetic kidney disease.

Renal failure·2026
Same journal

Development and validation of a dual-channel deep learning for continuous acute kidney injury prediction in critically ill patients.

Renal failure·2026
See all related articles

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Tacrolimus (FK506) is a critical immunosuppressive drug.
  • FK506 exhibits significant nephrotoxic properties, posing a clinical challenge.
  • The drug forms a complex with FKBP-12, influencing its biological activity.

Purpose of the Study:

  • To elucidate the mechanisms underlying Tacrolimus (FK506)-induced nephrotoxicity.
  • To explore the link between FK506's immunosuppressive and nephrotoxic effects via calcineurin inhibition.
  • To detail the spectrum of renal injury associated with FK506 treatment.

Main Methods:

  • Review of existing literature on FK506 pharmacology and nephrotoxicity.
  • Analysis of cellular and molecular pathways implicated in FK506-induced kidney damage.

Related Experiment Videos

  • Examination of the role of calcineurin inhibition in FK506's effects.

    • Main Results:

    • FK506-induced nephrotoxicity involves reduced renal blood flow and glomerular filtration rate.
    • Microvascular injury, endothelial damage, and tubular abnormalities (vacuolation, atrophy, calcification) are observed.
    • Interstitial fibrosis, mesangial cell proliferation, and inflammatory cytokine stimulation contribute to irreversible damage.

    Conclusions:

    • Calcineurin inhibition by the FK506-FKBP-12 complex is central to both immunosuppression and nephrotoxicity.
    • Dysregulation of calcium channels, inflammatory pathways (e.g., TGF-β), and vasoactive systems (renin-angiotensin, endothelin) mediate FK506's renal effects.
    • Understanding these mechanisms is crucial for managing FK506 nephrotoxicity and improving patient outcomes.